Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NYSE MKT | Common Stock
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease.
It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer.
In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).
Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications.
The company is based in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 24, 25 | -0.51 Decreased by -64.52% | -0.28 Decreased by -83.78% |
| Mar 27, 25 | -0.21 Increased by +38.24% | -0.39 Increased by +46.15% |
| Oct 31, 24 | -0.37 Increased by +24.49% | -0.37 Decreased by -0.90% |
| Aug 5, 24 | -0.38 Increased by +34.48% | -0.40 Increased by +5.00% |
| Apr 26, 24 | -0.31 Increased by +27.91% | -0.52 Increased by +40.38% |
| Mar 29, 24 | -0.34 Increased by +20.93% | -0.54 Increased by +37.04% |
| Nov 2, 23 | -0.49 Decreased by -28.95% | -0.53 Increased by +7.55% |
| Aug 14, 23 | -0.58 Decreased by -75.76% | -0.48 Decreased by -20.83% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -6.65 M Increased by +28.66% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -11.57 M Increased by +12.87% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -11.35 M Increased by +25.22% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -8.67 M Increased by +21.45% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 81.00 K Decreased by -28.95% | -9.32 M Increased by +6.79% | Decreased by -11.51 K% Decreased by -31.19% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -13.28 M Decreased by -45.11% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -15.18 M Decreased by -95.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -11.04 M Decreased by -116.67% | Decreased by N/A% Decreased by N/A% |